GH Research (GHRS) Stock Price, Analyst Forecasts, Price Targets, Ratings, News & Funds Holding
GHRS icon

GH Research

8.57 USD
At close Jan 10, 4:00 PM EST
1 day
0.00%
5 days
-8.83%
1 month
-4.46%
3 months
17.56%
6 months
-24.63%
Year to date
8.34%
1 year
40.49%
5 years
-55.48%
10 years
-55.48%
 

About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

Employees: 49

0
Funds holding %
of 6,810 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

7% more call options, than puts

Call options by funds: $29K | Put options by funds: $27K

0% more funds holding

Funds holding: 28 [Q2] → 28 (+0) [Q3]

0.38% less ownership

Funds ownership: 59.04% [Q2] → 58.66% (-0.38%) [Q3]

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

43% less capital invested

Capital invested by funds: $358M [Q2] → $204M (-$154M) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$28
227%
upside
Avg. target
$34
297%
upside
High target
$40
367%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
34% 1-year accuracy
53 / 158 met price target
367%upside
$40
Buy
Reiterated
10 Jan 2025
Canaccord Genuity
Sumant Kulkarni
38% 1-year accuracy
12 / 32 met price target
227%upside
$28
Buy
Maintained
18 Nov 2024

Financial journalist opinion

Neutral
GlobeNewsWire
9 hours ago
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
DUBLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones.
Positive
Zacks Investment Research
1 month ago
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?
The mean of analysts' price targets for GH Research (GHRS) points to a 225.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?
Neutral
GlobeNewsWire
1 month ago
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2024, and provided updates on its business.
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
Positive
MarketBeat
1 month ago
3 Fast-Growing Stocks Analysts See Doubling in Price
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise.
3 Fast-Growing Stocks Analysts See Doubling in Price
Positive
Zacks Investment Research
4 months ago
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
GH Research (GHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
Negative
Zacks Investment Research
4 months ago
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
GH Research (GHRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
Neutral
GlobeNewsWire
4 months ago
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business.
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
Neutral
GlobeNewsWire
4 months ago
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka “Villy” Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research.
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
Positive
InvestorPlace
6 months ago
3 Psychedelic Stocks to Ride to the Moon and Beyond
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
3 Psychedelic Stocks to Ride to the Moon and Beyond
Positive
Zacks Investment Research
7 months ago
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
GH Research (GHRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Charts implemented using Lightweight Charts™